Actavis rejected $15 billion offer from Mylan: source

By Soyoung Kim and Jessica Toonkel NEW YORK (Reuters) – Actavis Inc received and rejected a takeover offer from Mylan Inc last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation told Reuters on Tuesday. Mylan’s cash and stock bid for its larger rival, which came in early last week, valued Actavis at $120 per share, the person said, asking not to be identified because the matter is not public. …

Ultra-low salt intake may not boost health: U.S. panel

By Susan Heavey WASHINGTON (Reuters) – Americans at high risk for heart problems who have been told for years to sharply cut salt from their diet may not actually benefit from ultra-low sodium diets and could even face some harm, an independent panel of health experts said on Tuesday. The influential Institute of Medicine, in a report to U.S. health officials, reviewed the latest data on the link between salt intake and health. …

Jolie surgery sets good example by careful weighing of risks: doctors

By Julie Steenhuysen CHICAGO (Reuters) – Angelina Jolie’s decision to have a double mastectomy to prevent breast cancer may have stunned fans of the Oscar-winning actress, but doctors say her choice is shared by many other women with a high genetic risk for breast cancer. Jolie, who described her surgery and three-month recovery at length in an opinion piece in the New York Times on Tuesday, says she hopes her experience will encourage other women with a family risk of breast cancer to get tested. …

1 39 40 41 42 43 87